Deal Activity Highlights Interest In Bispecific Antibodies
This article was originally published in Pharmaceutical Approvals Monthly
Bispecific antibodies can be developed using many different formats for multiple therapeutic areas (see related story, (Also see "Is The Time Finally Right For Bispecific Antibodies?" - Pink Sheet, 16 Apr, 2013.)). Big pharmas have inked deals with modest upfront payments to explore the use of a variety of technology applications.
You may also be interested in...
Gilead will buy the Canadian cancer specialist for $510 million, gaining the lead drug CYT387, a JAK1/JAK2 inhibitor that has demonstrated positive results in myelofibrosis patients.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.